Opiranserin hydrochloride (Standard)
Opiranserin hydrochloride (Standard) is the analytical standard of Opiranserin (hydrochloride) (HY-109067A). This product is intended for research and analytical applications. Opiranserin (VVZ-149) hydrochloride, a non-opioid and non-NSAID analgesic candidate, is a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with IC50s of 0.86 and 1.3 μM, respectively. Opiranserin hydrochloride shows antagonistic activity on rP2X3 (IC50=0.87 μM). Opiranserin hydrochloride is development as an injectable agent for the treatment of postoperative pain.
For research use only. We do not sell to patients.
- CAS No.: 1440796-75-7
- Formula: C21H35ClN2O5
- Molecular Weight:430.97
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Purity & Documentation
-
Help & FAQs
-
HY-109067A
Opiranserin hydrochloride
-
HY-15209
Repaglinide
-
HY-130466
Stearoyl-L-carnitine chloride
-
HY-15209R
Repaglinide (Standard)
-
HY-110105
NS8593 hydrochloride
-
HY-138935
Iclepertin
-
HY-107527
Org 25543 hydrochloride
-
HY-B0500
Alverine citrate
-
HY-10716A
PF-03463275
-
HY-126486
AVE1231
-
HY-109067
Opiranserin
-
HY-130466R
Stearoyl-L-carnitine chloride (Standard)
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 1440796-75-7
-
Molecular Weight 430.97
-
Formula C21H35ClN2O5
-
SMILES
O=C(C1=CC(OC)=C(OCCCC)C(OC)=C1)NCC2(CCOCC2)N(C)C.[H]Cl
-
Synonyms
VVZ-149 hydrochloride (Standard)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Oh J, et al. Safety, Tolerability, and Pharmacokinetic Characteristics of a Novel Nonopioid Analgesic, VVZ-149 Injections in Healthy Volunteers: A First-in-Class, First-in-Human Study. J Clin Pharmacol. 2018 Jan;58(1):64-73. [Content Brief]
[2]. Nedeljkovic SS, et al. Randomised, double-blind, parallel group, placebo-controlled study to evaluate the analgesic efficacy and safety of VVZ-149 injections for postoperative pain following laparoscopic colorectal surgery. BMJ Open. 2017 Feb 17;7(2):e011035. [Content Brief]
[3]. Pang MH, et al. A series of case studies: practical methodology for identifying antinociceptive multi-target drugs. Drug Discov Today. 2012 May;17(9-10):425-34. [Content Brief]
[4]. Christopher L Cioffi. Inhibition of Glycine Re-Uptake: A Potential Approach for Treating Pain by Augmenting Glycine-Mediated Spinal Neurotransmission and Blunting Central Nociceptive Signaling. Biomolecules. 2021 Jun 10;11(6):864. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Opiranserin hydrochloride (Standard) Related Classifications
HY-109067AR Related Classifications
Powered by Bioz